Nirmatrelvir/Ritonavir (Paxlovid)
Treatment for Covid 19
Typical Dosage: Nirmatrelvir 300 mg / Ritonavir 100 mg orally twice daily
Effectiveness
85%
Safety Score
60%
Clinical Trials
45
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Nirmatrelvir 300 mg / Ritonavir 100 mg orally twice daily
Time to Effect
Within 3-5 days of symptom onset (when taken early)
Treatment Duration
5 days
Evidence Quality
HIGHNumber Needed to Treat (NNT)
19(Treat 19 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
500(Treat 500 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$530
Monitoring:$20
Side Effect Mgmt:$30
Total Annual:$580
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$14,000/QALY
QALYs Gained
0.03
Outcome-Based Costs
Cost per Responder
$682.35
Comparison vs No treatment / Supportive care
Cost Difference
+$300/year
More expensive
QALY Difference
+0.03 QALYs
Better outcomes
Dominance
No dominance
Nirmatrelvir/Ritonavir (Paxlovid) Outcomes
for Covid 19
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+85%
Common Side Effects
Dysgeusia (altered taste)
+25%
Diarrhea
+8%
Nausea
+6%
Drug-drug interactions
+5%
Active Clinical Trials
3 active trials recruiting for Nirmatrelvir/Ritonavir (Paxlovid) in Covid 19
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
NCT07089680NOT YET RECRUITING
1.2K participants
OBSERVATIONAL
Started: Aug 18, 2025
A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
NCT07261085ACTIVE NOT RECRUITING
99K participants
OBSERVATIONAL
New York, United States
Started: Oct 27, 2025
PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway
NCT05852873ACTIVE NOT RECRUITINGPHASE3
2K participants
INTERVENTIONAL
Bergen, Norway
Started: May 12, 2023
Completed Clinical Trials
11 completed trials for Nirmatrelvir/Ritonavir (Paxlovid) in Covid 19
Saliva PCR in Pregnant Women with COVID-19
NCT06735300COMPLETED
37 participants
OBSERVATIONAL
Tainan, Taiwan
Started: Jun 1, 2022
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
NCT07072793COMPLETED
131K participants
OBSERVATIONAL
New York, United States
Started: Oct 31, 2024
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
NCT05263908COMPLETED
3.35K participants
OBSERVATIONAL
Tokyo, Japan
Started: Mar 31, 2022
A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
NCT06016556COMPLETED
250 participants
OBSERVATIONAL
Jeddah, Saudi Arabia +2 more
Started: Oct 17, 2023
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
NCT07090486COMPLETED
14K participants
OBSERVATIONAL
New York, United States
Started: Apr 15, 2025
Efficacy and Safety of JT001 (VV116) Compared With Paxlovid
NCT05341609COMPLETEDPHASE3
822 participants
INTERVENTIONAL
Shanghai, China +6 more
Started: Apr 4, 2022
The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19
NCT06349655COMPLETED
32.9K participants
OBSERVATIONAL
Zhengzhou, China
Started: Dec 5, 2023
Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir
NCT05624840COMPLETED
85 participants
OBSERVATIONAL
Shatin, Hong Kong
Started: Nov 7, 2022
A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.
NCT06291831COMPLETED
3.01K participants
OBSERVATIONAL
Busaiteen, Bahrain
Started: Mar 13, 2024
ImPROving Quality of LIFe in the Long COVID Patient
NCT05823896COMPLETEDPHASE2
219 participants
INTERVENTIONAL
Stockholm, Sweden
Started: May 1, 2023
Paxlovid for Treatment of Long Covid
NCT05576662COMPLETEDPHASE2
168 participants
INTERVENTIONAL
Stanford, United States
Started: Nov 8, 2022
Showing 20 of 46 total trials